Quince Therapeutics (QNCX) News Today → Mysterious Gold Leverage Just Announced (From Stansberry Research) (Ad) Free QNCX Stock Alerts $1.03 -0.03 (-2.83%) (As of 04/25/2024 ET) Add Compare Share Share HeadlinesStock AnalysisChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial Media All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative SourceHeadlineQNCX Stock Earnings: Quince Therapeutics Reported Results for Q4 2023investorplace.com - April 2 at 10:04 AMQuince Therapeutics Provides Business Update and Reports Fourth Quarter and Fiscal 2023 Financial Resultsfinance.yahoo.com - April 1 at 10:21 AMQuince Therapeutics Launches Scientific Advisory Boardfinance.yahoo.com - February 22 at 8:08 AMQuince Therapeutics Launches Scientific Advisory Boardbusinesswire.com - February 22 at 7:00 AMQuince Therapeutics Appoints Former Reata Pharmaceuticals Chief R&D Officer Dr. Rajiv Patni to its Board of Directorsfinance.yahoo.com - February 15 at 10:41 AMQuince Therapeutics, Inc. (NASDAQ:QNCX) Sees Significant Drop in Short Interestmarketbeat.com - February 15 at 7:44 AMQuince Therapeutics Appoints Former Reata Pharmaceuticals Chief R&D Officer Dr. Rajiv Patni to its Board of Directorsbusinesswire.com - February 15 at 7:00 AMQuince Therapeutics (NASDAQ:QNCX) Stock Price Down 8.5%marketbeat.com - February 14 at 3:18 AMQuince Therapeutics to Participate at Investor Events in January 2024finance.yahoo.com - January 4 at 5:54 PMQuince Therapeutics Inc QNCXmorningstar.com - November 11 at 9:31 AMChief Business Officer and COO at Quince Therapeutics Acquires Company Stock Options Worth 75,000 Sharesbenzinga.com - October 27 at 1:31 PMQuince Therapeutics Chief Scientific Officer Awarded $291K Worth of Stock Optionsbenzinga.com - October 25 at 1:46 PMQuince Therapeutics Completes Acquisition of EryDel S.p.A.finance.yahoo.com - October 23 at 8:49 AMFDA lifts partial clinical hold on EryDel lead product EryDexmsn.com - September 28 at 7:04 PMU.S. FDA Partial Clinical Hold Lifted on IND for EryDel’s Lead Phase 3 Asset EryDex for the Treatment of Ataxia-Telangiectasiafinance.yahoo.com - September 28 at 7:04 PMQuince Therapeutics President Awarded $692K Worth of Stock Optionsbenzinga.com - September 7 at 6:59 PMDaily Digest: Currys aim to raise $50M for Oakland schools; Sotheby's opens new officebizjournals.com - September 6 at 4:43 PMQuince Therapeutics Appoints Dr. Charles S. Ryan as Presidentfinance.yahoo.com - September 6 at 9:25 AM325K Reasons To Be Bullish On Quince Therapeutics Stockbenzinga.com - August 18 at 5:37 PMQuince Therapeutics And 2 Other Stocks Under $3 Insiders Are Buyingbenzinga.com - August 14 at 6:07 PMQuince Therapeutics to Present at Sidoti Virtual Investor Conference on August 17, 2023finance.yahoo.com - August 11 at 2:28 AMQUINCE THERAPEUTICS INCfinanznachrichten.de - July 26 at 4:45 PMWhat's Going On With Quince Therapeutics Stock Todaybenzinga.com - July 24 at 2:59 PMQuince Therapeutics to Acquire EryDel SpA and its Phase 3 Asset Targeting Ataxia-Telangiectasia with No Currently Approved Treatments and Estimated $1+ Billion Peak Sales Opportunityfinance.yahoo.com - July 24 at 8:07 AMEcho Lake bumps up bid to buy Quince Therapeutics to $1.80msn.com - July 13 at 1:56 PMEcho Lake bumps up bid to buy Quince Therapeutics to $1.80/shareseekingalpha.com - July 13 at 1:56 PMEcho Lake Capital Increase Offer to Acquire Quince Therapeutics, Inc.finance.yahoo.com - July 13 at 8:55 AMEcho Lake Capital: Echo Lake Criticizes Quince Therapeutics Board for Enriching Themselves While Destroying Significant Shareholder Valuefinanznachrichten.de - June 6 at 8:33 AMEcho Lake Criticizes Quince Therapeutics Board for Enriching Themselves While Destroying Significant Shareholder Valuefinance.yahoo.com - June 6 at 8:33 AMQuince Therapeutics Board of Directors Unanimously Rejects Unsolicited Proposal from Echo Lake Capitalfinance.yahoo.com - April 11 at 8:06 AMQuince Therapeutics: A Company Without A Suitable Planseekingalpha.com - April 6 at 10:34 PMCash-rich life sciences companies are targets. Activist investors are taking aim.bizjournals.com - April 6 at 5:34 PMQuince Therapeutics Engages MTS Health Partners as Independent Financial Advisorfinance.yahoo.com - April 6 at 5:34 PMQuince Therapeutics adopts poison pill amid unsolicited takeover offerseekingalpha.com - April 5 at 9:33 PMQuince Therapeutics Adopts Limited Duration Stockholders Rights Planfinance.yahoo.com - April 5 at 4:33 PMQuince Therapeutics Confirms Receipt of Unsolicited Acquisition Offer from Echo Lake Capitalbusinesswire.com - March 22 at 5:12 AMQuince Therapeutics shares are trading higher after Echo Lake Capital offered to acquire the company for $1.60 per share in cash.benzinga.com - March 21 at 12:45 PMQuince stock surges ~50% on acquisition offer from Echo Lake Capitalmsn.com - March 21 at 12:45 PMEcho Lake Capital Offers to Acquire Quince Therapeutics, Inc.finance.yahoo.com - March 21 at 12:45 PMQuince expects ~$11M annual capital and operating expenditures in 2023msn.com - January 30 at 5:53 PMQuince Therapeutics Provides Pipeline Update and Business Outlook for 2023finance.yahoo.com - January 30 at 5:53 PMCasey Lynch and her Cortexyme team regroup at Lighthouse for another shot at Alzheimer'sbizjournals.com - January 27 at 7:56 PMWhy Is Quince Therapeutics (NASDAQ:QNCX) Stock Up 53% Today?investorplace.com - January 27 at 11:02 AMQuince Therapeutics Completes the Sale of Legacy Protease Inhibitor Portfolio to Lighthouse Pharmaceuticalsfinance.yahoo.com - January 27 at 8:16 AMQuince Therapeutics Inc.barrons.com - January 15 at 2:20 PMWe Think Quince Therapeutics (NASDAQ:QNCX) Needs To Drive Business Growth Carefullyfinance.yahoo.com - November 21 at 11:55 AMQuince Therapeutics Inc (QNCX)investing.com - October 1 at 1:11 PMQuince Therapeutics to Present at Canaccord Genuity 42nd Annual Growth Conference on August 11, 2022finance.yahoo.com - September 26 at 8:21 AMQuince Therapeutics to Present at Upcoming Scientific Meetingsfinance.yahoo.com - September 26 at 8:21 AMQuince Therapeutics Presents Preclinical Data at OI 2022 Demonstrating Potential of a Targeted Anabolic for Accelerated Bone Healing of Osteogenesis Imperfecta Fracturesfinance.yahoo.com - September 26 at 8:21 AM Get Quince Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for QNCX and its competitors with MarketBeat's FREE daily newsletter. Email Address Mysterious Gold Leverage Just Announced (Ad)World's biggest multibillionaire investor group is buying THIS by the tons Most folks have completely missed the fact that there's one group of investors so powerful they're literally buying ONE THING by the tons… Stacking it in their locked vaults on pallets in record numbers. Find out what it is and see how you can get in with just a few dollars. QNCX Media Mentions By Week QNCX Media SentimentLearn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. QNCX News Sentiment▼0.000.41▲Average Medical News Sentiment QNCX News CoverageLearn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. QNCX Articles This Week▼00▲QNCX Articles Average Week Get Quince Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for QNCX and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies: OKYO Pharma News Tevogen Bio News Cyclo Therapeutics News Dyadic International News Protara Therapeutics News Achilles Therapeutics News MiNK Therapeutics News IN8bio News Pluri News NKGen Biotech News Headlines Tools: Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:QNCX) was last updated on 4/25/2024 by MarketBeat.com Staff From Our PartnersThese AI trades triggered this morning (545% return)Prosper Trading AcademyThe Best AI Stock to Own in the World Today is Trading for Just $25Banyan Hill PublishingConflict In Israel Sends Gold Soaring ???? Here’s How To Get Your ShareColonial MetalsThe A.I. story nobody is telling you (Read ASAP)TradeSmithHe Is Giving Away BitcoinCrypto Swap ProfitsYour Money is Not SafeAmerican AlternativeJim Cramer’s “The Biggest Drug Ever”Behind the MarketsThe only accurate crypto trading system I know …Weiss Ratings Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Quince Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
